Cerenome, Inc. CNSY
0.70 USD -0.19 (-21.62%)
Nov 5, 2026, 1:01 PM EST
0.63 Day range 0.87
0.63 52-week range 19.00
- YTD
- -94.52%
- 1 year
- -94.82%
- Market cap
- 5.30M
- EPS (ttm)
- -3.36
- YTD return
- -94.52%
- 1-year return
- -94.82%
- Volume
- 871.45K
- Avg volume
- 595.03K
- Open
- 0.87
- Previous close
- 0.8916
- Day's range
- 0.63 – 0.87
- 52-week range
- 0.63 – 19.00
5Y -681.6659 (-99.88%)
Financials — quick view
CNSY Revenue — quarterly 411.00K
CNSY Net income — quarterly -9.01M
CNSY EPS — quarterly -1.31
News
12 Health Care Stocks Moving In Wednesday's Intraday Session 
CNSide Diagnostics Inks National In-Network Laboratory Ancillary Provider With Aetna Health Plans 
Cerenome Secures National In-Network Agreement with Aetna for CNSide® - 12 Health Care Stocks Moving In Tuesday's Intraday Session
Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma 
Cerenome To Report Poster Presentation Of Interim Data From Its Current ReSPECT-LMM Multidose Trial Of REYOBIQ At 31st Annual Meeting And Education Day 
Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases 
New Strong Sell Stocks for October 22nd - Cerenome Presents New Preclinical Data At 16th Biennial Rivkin Ovarian Cancer Research Symposium Regarding Immunomodulatory Properties Of REYOBIQ
Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™
Your note
Sign in to keep a note on CNSY — it syncs with the Stock Master app.